INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary Conkwest Announces $50M in Strategic Investments and Appoints Nantworks Founder, Dr. Patrick Soon-Shiong as Co-Chairman of the Board
SAN DIEGO (December 24, 2014) —Conkwest, Inc., the N atural K iller Cell Co mpany of the West, developing the proprietary Natural Killer (NK) cell-line platform, Neukoplast ® as an immuno-oncology therapeutic, announces that Dr. Patrick Soon-Shiong, NantWorks founder, physician scientist and
View HTML
Toggle Summary Sorrento and Conkwest Announce Exclusive Global Collaboration Developing Next Generation Cancer Immunotherapy with “Off-the-Shelf” Chimeric Antigen Receptor–Tumor Attacking Natural Killer (CAR-taNK™) Cell Lines
San Diego and Cardiff-by-the-Sea, CA (Dec. 19, 2014) — Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, and Conkwest, Inc., a privately-held immuno-oncology company developing proprietary Neukoplast ® , a Natural
View HTML